Previous close | 241.88 |
Open | 243.27 |
Bid | 244.04 x 800 |
Ask | 247.02 x 900 |
Day's range | 242.69 - 246.59 |
52-week range | 229.86 - 287.32 |
Volume | |
Avg. volume | 1,472,524 |
Market cap | 71.223B |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | 56.54 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.80 (1.54%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
Becton Dickinson said on Thursday it has increased production of medical syringes in the United States after the country's drug regulator recommended not using some China-made syringes as part of its ongoing quality probe. The U.S.-based medical equipment maker — one of the world's largest syringe suppliers — said it had increased manufacturing in its Nebraska and Connecticut facilities, since the U.S. Food and Drug Administration first raised concerns about China-made syringes in November. The FDA had said last year it was looking into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China and that it may prevent such syringes from entering the U.S. market, if necessary.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.